A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Psychosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- June 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Gilbert Neurology Partners/CCT Research · Gilbert, AZ
California · 1
- Inland Psychiatric Medical Group. · Chino, CA
Ohio · 1
- Insight Clinical Trials LLC - Independence · Independence, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.